ClinicalTrials.gg
Drug

Glucagon clinical trials

Also written LY900018, GlucaGen, AMG504-1 and Baqsimi.

Includes 1 study of Glucagon hydrochloride.

studies test it
81
open now
5
in phase 3
13
first study started
2005

How each study uses Glucagon is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Glucagon studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
14 Nov 1960 · GLUCAGON · NDA 012122 (FDA, Drugs@FDA; as glucagon hydrochloride)
European Union
16 Dec 2019 · Baqsimi · EMEA/H/C/003848 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Glucagon
48
Nasal Glucagon
10
Glucagon for Injection (Fresenius Kabi USA)
3
Glucagen Hypokit
3
G-Pen Mini™ (glucagon injection)
3

Brand

GlucaGen
9
Baqsimi
2

Development codes

LY900018
13
AMG504-1
9

Studies by the year they started

79 studies that test it; most in 2017 (9); 1 more planned to start later

Studies that test Glucagon, by start year
YearStudies
20051
20061
20071
20081
20092
20113
20122
20138
20146
20158
20166
20179
20188
20196
20202
20214
20223
20232
20242
20264

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
21
Phase 2
22
Phase 3
13
Phase 4
12
No phase
16

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 31 · Other 50

Eli Lilly and Company (13) · Xeris Pharmaceuticals (11) · Steno Diabetes Center Copenhagen (6) · Institut de Recherches Cliniques de Montreal (4) · Joslin Diabetes Center (3) · University Health Network, Toronto (3) · Legacy Health System (3) · AdventHealth Translational Research Institute (2)

Often tested with

Tested in the same studies.

Glucose (4) · Somatostatin (2) · Insulin, Regular, Human (2) · Octreotide (2) · Human Growth Hormone (2) · Insulin (2) · Exenatide (1) · Dasiglucagon (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4

Studies that test Glucagon.

Studies

Open first, then newest update. How each study uses Glucagon is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 81

See all 81 studies that test Glucagon →

Given beside what is tested · 14 — Glucagon is usual care or a partner of the new treatment
As the comparator · 11 — what is tested is compared with Glucagon

Codes

What other systems call Glucagon · ClinicalTrials.gg INT007556

  • MeSH (NLM) D005934GlucagonOne source ClinicalTrials.gov
  • UNII (FDA) 76LA80IG2GGLUCAGONOne source FDA
  • RxNorm 4832One source FDA
  • NCI Thesaurus C520Recombinant GlucagonOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.